The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.La presente descripción se refiere a compuestos descritos que aumentan la actividad del regulador de conductancia transmembrana de la fibrosis quística (CFTR) tal como se mide en células epiteliales bronquiales humanas (hBE).